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Abstract
Based on a 3D-QSAR pharmacophore derived from a diverse set of known cyclin-dependent 
kinase 9 (CDK9) inhibitors and a composite pharmacophore extracted from the complex structure 
of flavopiridol (FVP)-CDK9, thirty novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamine 
derivatives were designed and synthesized. Initial tests against four tumor cell lines with the 
sulforhodamine B (SRB) assay identified a series of potent compounds with GI50 values at lower 
micromolar or submicromolar level. Most of the highly cytotoxic compounds exhibited potent 
inhibitory activities against both CDK2/cyclin E1 and CDK9/cyclin T1. Notably, inhibitions 
against the two enzymes were generally correlated well with the cytotoxicity of these compounds. 
Appreciable inhibition was also observed for selected compounds in the anti-HIV-1 assay. 
Docking studies on compounds 6d and 9g provided conducive clues to further structural 
optimization.
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1. Introduction
Cyclin-dependent kinases (CDKs) are a family of serine/threonine protein kinases involved 
in the control of cell cycle and the regulation of gene transcription. Once bound to the 
regulatory subunit cyclins, CDKs can phosphorylate the downstream substrates and activate 
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various cellular processes. Due to their intense involvement in many physiological processes 
and diseases, CDKs have attracted extensive research interests1. Several of the CDKs play 
critical roles in cell cycle progression and a number of CDK inhibitors are currently under 
clinical trials for the treatment of various cancers2. As a member of the CDK family, CDK9 
plays a pivotal role in transcriptional regulation and is regarded as a potential target in 
oncology, virology and cardiology3. CDK9 complexes with cyclin T to form transcription 
elongation factor b (P-TEFb) and regulate gene transcription by phosphorylating the C-
terminus of the large subunit of RNA polymerase II. It has been reported that differential 
effects on HIV replication and T-cell activation were observed upon direct inhibition of the 
P-TEFb kinase activity in primary human peripheral blood lymphocytes4. Therefore, 
selective CDK9 inhibitors have been actively pursued5–9 and evaluated as potentially 
effective agents to block HIV-1 replication5–7. The X-ray crystal structures of these 
inhibitors complexed with CDK9 as well as CDK2 have been resolved and analyzed to 
investigate the structural basis for isotype selectivity10–12. Nevertheless, recent studies13,14 
have also suggested implication of CDK2 in HIV-1 transcription regulation through 
functional link with CDK9 (for example, by phosphorylating CDK9 14). Therefore, 
compounds with good potency against CDK2 and CDK9 might be therapeutically useful in 
the treatment of cancer and HIV infection.
To search for new CDK inhibitors, especially CDK9 inhibitors as anti-cancer and anti-HIV 
agents, we have previously established quantitative pharmacophore models based on a 
diverse set of CDK9 inhibitors15. The most representative model depicted a pharmacophore 
with two hydrogen-bond acceptor features and two hydrophobic aromatic features. As 
illustrated in Figure 1a, such pharmacophore matches well with the chemical features of 
flavopiridol (FVP), a flavonoid pan-CDK inhibitor and the most potent inhibitor against P-
TEFb identified to date16. The interaction mode of FVP with CDK9 has been revealed by 
the crystal structure of the FVP-CDK9 complex17. As shown in Figure 1b, the FVP 
molecule occupies the ATP-binding site of CDK9. The O4 oxygen and the O5 hydroxyl of 
FVP form hydrogen bonds with the CDK9 hinge residues Cys106 and Asp104, respectively. 
An additional hydrogen bond is observed between the O3 hydroxyl and the Asp167 side 
chain. Moreover, the chloro-phenyl ring of FVP makes hydrophobic contacts with Ile25, and 
the protonated N1 of the piperidinyl group presents electrostatic interaction with Asp167. 
Therefore, a composite pharmacophore with three hydrogen bond forming atoms, one 
hydrophobic aromatic center and one positively charged center was constructed (Figure 1c). 
Remarkably, the quantitative and the composite pharmacophore models are in good 
consistency.
We report herein the design, synthesis and biological evaluation of a series of novel 5-
fluoro-N2,N4-diphenylpyrimidine-2,4-diamine derivatives. This novel class of compounds 
were designed by following a pharmacophore-oriented scaffold-hopping strategy. The 
hybrid pharmacophore combining key features in the 3D-QSAR and composite models 
demonstrated in Figure 1 was used to guide the molecular design (Figure 2). To ensure 
kinase inhibition and convey structural novelty, the 2-aminopyrimidine core structure, which 
is a privileged scaffold for CDK inhibitors8,18,19, was utilized for the design. 5-Fluoro 
substitution was introduced according to previous structure-activity relationship studies on 
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CDK9 inhibitors with the 2-anilino-4-heteroarylpyrimidine scaffold8,18. The general formula 
and the pharmacophoric features of the target compounds are shown in Figure 2.
2. Results and discussion
2.1 Chemistry
The general synthetic route for compounds 6a-6f was shown in Scheme 1. Compound 2a 
was prepared through a cross-coupling reaction between 1-bromo-3-nitrobenzene (1a) and 
morpholine20, and then followed by catalytic hydrogenation to afford compound 3a. 
Compounds 3b and 3c were synthetized similarly. Compounds 5a-5d were prepared by 
regio-selective substitution of the appropriate amines to 2,4-dichloro-5-fluoropyrimidine21. 
Further substitutions between 3a-3c and 5a-5d in alcoholic solvent afforded the target 
compounds 6a-6f 22.
The preparation of compounds 9a-9h and 11a-11p was also illustrated in Scheme 1. 
Compound 5b was reacted with m-nitroaniline and m-aminobenzoic acid to give compounds 
7 and 10, respectively. Catalytic hydrogenation of compound 7 in the presence of Pd/C 
produced compound 8. Both 8 and 10 were subjected to condensation reactions under the 
treatment of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium 
hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIEA) to afford the target 
amide compounds 9a-9h and 11a-11p 23.
2.2 Biological evaluation
All the target compounds were initially tested against the tumor cell lines of A594, DU145, 
KB and KBvin with the sulforhodamine B (SRB) assay. The inhibitory activities of the 
compounds in terms of GI50 values were shown in Tables 1, 2 and 3.
The cytotoxic results suggested that fluoro-substitution on 4-anilino might be important for 
the anti-proliferative effects (6a and 6b versus 6c and 6d). Therefore, p-fluoroanilino was 
retained at R2, while methoxyl substitution was introduced at R3 (6e), and morpholino was 
further replaced with 4-methylpiperazin-1-yl (6f) to explore their effects on cytotoxicity. 
Although the introduction of methoxyl group at R3 decreased the inhibitory activity (6c 
versus 6e), the presence of 4-methylpiperazin-1-yl instead of morpholino at R1 significantly 
increased potency (6e versus 6f). Such observation implicated that the electrostatic 
interaction between the residue Asp167 and the protonated nitrogen in the piperidinyl group 
is more advantageous over the hydrogen bonding interaction between the oxygen atom in 
the morpholino moiety and Asp167. Therefore, positively charged atoms should be preferred 
in the close proximity to R1.
Compounds 9a-9h and 11a-11p retained the p-fluoroanilino at R2, while incorporating 
diverse R1 substituents with different sizes, electronic effects and hydrogen bond forming 
capability to further investigated the structure-activity relationships at this molecular area. 
For both compounds 9 and 11, aliphatic substituents, either linear or cyclic, were generally 
favored over aromatic substituents at R1. The results implied that the R1 substituents might 
serve as a counterpart of the sugar moiety in the ATP structure, therefore, aliphatic 
substituents might be more likely to meet the requirements for optimal pharmacophoric 
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orientation and molecular shape of CDK inhibitors. In addition, compounds with a 
positively charged center were more potent than their congeners with only hydrogen bond 
forming atoms (9g versus 9h; 11a versus 11b; 11f versus 11g), which suggests the 
importance of electrostatic interactions in this molecular area. The series 9 were generally 
more potent than the series 11. For compounds with aromatic substituents at R1 of 9, 
electron-withdrawing groups might be preferred over electron-donating moieties for 
cytotoxicity (9b versus 9c; 9a versus 9d). However, electrostatic properties showed no 
definite effects on the cytotoxicity of compounds in series 11.
Nine of the most cytotoxic compounds were further evaluated against CDK2/cyclin E1 and 
CDK9/cyclin T1. Most of these compounds exhibited potent inhibitory activities against 
both systems (Table 4). Due to limited data, it is difficult to deduce informative SAR from 
the results. However, for most compounds, the molecular potency generally correlated well 
with the cellular cytotoxicity, which indicated that CDK inhibition might be responsible for 
the cytotoxicity of these compounds. Compound 6f was the only exception. The discrepancy 
between cellular and molecular activities of compound 6f implicated the involvement of 
alternative molecular mechanisms other than CDK inhibition. For all the compounds tested 
at molecular level, only compounds 6d and 9d showed moderate selectivity to CDK9 over 
CDK2.
To determine whether selective CDK9 inhibition correlates with anti-HIV activity, three 
compounds (6d, 11e and 11f) with different level of selectivity to CDK9 were tested in an 
anti-HIV-1 assay. Appreciable inhibition was observed for all three compounds. Notably, 
the results did reveal a trend that higher selectivity to CDK9 might lead to better therapeutic 
index (Table 5). Further validation with more CDK9 inhibitors is undergoing.
2.3 Molecular modeling
Docking studies on selected compounds were performed to recognize their interaction 
modes with CDKs. As exemplified by the docking poses of compound 9g in the ATP-
binding sites of CDK9, two alternative binding poses were suggested (Figure 3). For pose A 
(Figure 3a), the molecule assumed an orientation similar to that of FVP. Besides the 
hydrogen bond between N-1 atom of the pyrimidine ring and Cys106, additional hydrogen 
bonds were observed between the 2-amino and Asp104, as well as the carboxyl oxygen and 
Asp167. Electrostatic interaction between the nitrogen in N,N-dimethyl glycine and Asp167 
were also monitored. Alternatively, compound 9g could also adopt pose B (Figure 3b). It 
was a turnover of pose A, where the N,N-dimethyl glycine moiety occupied the hydrophobic 
subpocket engaged by the chloro-phenyl of FVP. The N-1 atom and 2-amino moiety on the 
pyrimidine ring interacted with the hinge residue Cys106 of CDK9 through hydrogen 
bonding, while the 4-anilino group protruded toward Asp167. The electron-withdrawing 
fluoro-substitution on N4-phenyl made it electron deficient and presented electrostatic 
interaction with Asp 167. The disclosure of alternative binding poses of this compound class 
might provide new clues for further structural optimization.
Compound 6d, the inhibitor with the highest selectivity toward CDK9, was docked to both 
CDK2 and CDK9 to provide insights on structural basis for selective CDK9 inhibition. As 
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shown in Figure 4, compound 6d bound to the ATP sites of CDK2 and CDK9 with an 
orientation different from that of FVP. It adopted a pose similar to pose B in Figure 3b. The 
prevalence of pose B for 6d could be attributed to its structural features in R1 and R2. Due to 
the absence of protonable nitrogen in R1, the electrostatic interaction between R1 and 
Asp145 in CDK2 or Asp167 in CDK9 was missed. On the other hand, the electron-
withdrawing difluoro-substitution (R2) on N4-phenyl strengthened its interaction with 
Asp145 (CDK2) or Asp167 (CDK9).
As indicated in Figure 4, the key interactions of 6d in CDK2 and CDK9 were similar. 
Hydrogen bonds existed between N-1 atom/2-amino moiety of 6d and the hinge residue 
(Leu83 for CDK2 and Cys105 for CDK9). The difluoro-substituted N4-phenyl ring extended 
to the proximity of Asp145 (CDK2) or Asp167 (CDK9). The most obvious difference 
between the interaction modes of 6d with CDK2 and CDK9 was the orientation of the 
morpholino ring in R1. Compound 6d assumed a condensed U-conformation in the ATP-
binding site of CDK2, and the morpholino ring was virtually parallel to the N4-phenyl ring 
(Figure 4a). While, it was more extended in the binding site of CDK9 and the morpholino 
ring was basically vertical to the N4-phenyl ring. The changing of the Lys89 in CDK2 to 
Gly122 in CDK9 was responsible for the discrepancy in the interaction modes. Due to such 
a difference, the binding site of CDK9 is relatively larger and can accommodate more steric 
moieties in R1. The lone pair interaction between the nitrogen atom in morpholino and the 
Lys89 in CDK2 might cause further shift of the morpholino ring toward the N4-phenyl. The 
structural insights gained from docking studies might guide further molecular design of 
selective CDK9 inhibitors.
3. Experimental
3.1 Materials and methods
All reactions were monitored by thin-layer chromatography with pre-coated silica gel F254 
plates purchased from Merck, Inc. All melting points were determined on Yanaco Melting 
point apparatus and are uncorrected. Mass spectra (MS) were taken in HR-ESI mode on 
Exactive Plus™ LC/MSD Orbitrap from Thermo Fisher Scientific. 1H-NMR spectra were 
recorded on Varian Mercury 300-MHz spectrometer. Chemicals were obtained from local 
suppliers and were used without further purification.
3.2 Chemistry
3.2.1 Preparation of compound 3—2-Nitro-4-bromoanisole (2.32 g, 10 mmol), 
morpholine (3.58 g, 40 mmol), CuI (0.19 g, 0.1 mmol), L-proline (0.23 g, 2 mmol) and 
K2CO3 (2.76 g, 20 mmol) were dissolved in 20 ml DMSO and stirred under nitrogen for 48 
h at 100 °C. After cooling to room temperature, the reaction mixture was poured into water 
and extracted with ethyl acetate, the combined organic layers were successively washed by 
water and saturated solution of Na2CO3. The organic layer was dried over Na2SO4, and 
filtered. The solvents were removed under reduced pressure and the crude material was 
purified by column chromatography on silica gel, eluted with petroleum ether/ethyl acetate 
(10:1) to afford compound 2b as a yellow oil (1 g, 42%).
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Compound 2b (1 g, 4.8 mmol) and Pd/C (0.1 g) were added in methanol and stirred under 
hydrogen atmosphere for 24 h at room temperature. Pd/C was filtered by diatomite and the 
solvents were removed under reduced pressure. The crude material was purified by column 
chromatography on silica gel, eluted with petroleum ether/ethyl acetate (2:1) to afford 
compound 3b as a white solid (0.3 g, 34%).
Compounds 3a and 3c were synthetized from different start materials using the same 
procedure as described.
3.2.2 Preparation of compound 5—2,4-Dichloro-5-fluoro-uricpyrimidine (4, 1.67 g, 10 
mmol), p-fluoro-aniline (1.11 g, 10 mmol) and trifluoroacetic acid (1.52 g, 15 mmol) were 
mixed in 10 ml ethanol and stirred for 24 h at room temperature. The precipitation was 
filtered and then washed by ethanol, dried over Na2SO4, and filtered. The solvents were 
removed under reduced pressure getting 5b as a white solid (2.4 g, 99%).
Compound 5a, 5c and 5d were synthetized from different starting materials with the same 
procedure as described.
3.2.3 Preparation of compound 6—To a solution of compound 3a (122 mg, 0.687 
mmol) and compound 5d (200 mg, 0.687 mmol) in 10 ml isopropanol, one drop of acetic 
acid was added. The reaction mixture was stirred at 110 °C and was refluxed for 24 h. After 
cooling to room temperature, the precipitation was filtered to get compound 6d as a white 
solid (200 mg, 40%).
Compounds 6a-6c and 6e-6f were synthetized from different starting materials using the 
same procedure as described.
Compound 6a: yield: 67 %, mp: 189–190°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.07 (s, 
1H), 9.74 (s, 1H), 8.28 (d, J = 3.9 Hz, 1H), 7.87 (s, 2H), 7.31 (s, 1H), 7.15–7.18 (m, 3H), 
6.74 (s, 1H), 3.74 (s, 4H), 3.08 (s, 4H). HR-ESI-MS: m/z = 434.0942 [M+H]+, calcd for 
C20H19N5OFCl2: 434.0945.
Compound 6b: yield: 90%, mp: 196–198°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.40 (s, 
1H), 10.14 (s, 1H), 8.32 (d, J = 4.2 Hz, 1H), 8.04 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 7.2 Hz, 
1H), 7.56 (d, J = 8.7 Hz, 1H), 7.18–7.25 (m, 2H), 7.09 (d, J = 7.5 Hz, 1H), 6.81 (d, J = 6.6 
Hz, 1H), 3.73 (s, 4H), 3.06 (s, 4H). HR-ESI-MS: m/z = 434.0952 [M+H]+, calcd for 
C20H19N5OFCl2: 434.0945.
Compound 6c: yield: 47%, mp: 220–222°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.36 (s, 
1H), 9.03 (s, 1H), 8.08 (d, J = 3.6 Hz, 1H), 7.78 (dd, J = 5.1, 9.3 Hz, 2H), 7.21 (s, 1H), 7.12 
(t, J = 6.6 Hz, 3H), 7.05 (t, J = 8.1 Hz, 1H), 6.50 (d, J = 7.5 Hz, 1H), 3.68 (t, J = 4.8 Hz, 
4H), 2.96 (t, J = 4.8 Hz, 4H). HR-ESI-MS: m/z = 384.1625 [M+H]+, calcd for 
C20H20N5OF2: 384.1630.
Compound 6d: yield: 40%, mp: 181–183°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.19 (s, 
1H), 8.92 (s, 1H), 8.10 (d, J = 3.3 Hz, 1H), 7.36–7.43 (m, 1H), 7.22 (t, J = 8.1 Hz, 2H), 7.02 
(t, J = 8.4 Hz, 2H), 6.85 (t, J = 8.1 Hz, 1H), 6.41 (d, J = 6.9 Hz, 1H), 3.66 (t, J = 4.8 Hz, 
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4H), 2.90 (t, J = 4.8 Hz, 4H). HR-ESI-MS: m/z = 402.1534 [M+H]+, calcd for 
C20H19N5OF3: 402.1536.
Compound 6e: yield: 23%, mp: 195–198°C, 1H NMR (400MHz, DMSO-d6): δ 9.40 (s,1H), 
8.09(d, J = 3.6 Hz,1H), 7.70-7.67 (m,4H), 7.12 (t, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 1H), 
6.51 (dd, J = 2.8, 8.8 Hz, 1H), 3.76 (s, 3H), 3.64 (t, J = 4.4 Hz, 4H), 2.82 (t, J = 4.4 Hz, 4H). 
HR-ESI-MS: m/z = 414.1728 [M+H]+, calcd for C20H21N2O5: 414.1736.
Compound 6f: yield: 21%, mp: 71–73°C, 1H-NMR ( 300 MHz, DMSO-d6): δ 9.40 (s, 1H), 
8.09 (d, J = 5.4 Hz, 1H), 7.71-7.64 (m, 4H), 7.11 (t, J = 8.5 Hz, 2H), 6.86 (d, J = 9.0 Hz, 
1H), 6.52 (dd, J= 3.9, 5.4 Hz, 1H), 3.75 (s, 3H), 2.87 (m, 4H), 2.38 (m, 4H), 2.20 (s, 3H). 
HR-ESI-MS: m/z = 427.2040 [M+H]+, calcd for C22H25N6O F2: 427.2052.
3.2.4 Preparation compound 8—Compound 5b (2.42 g, 10 mmol), m-nitroaniline (1.38 
g, 10 mmol) and trifluoroacetic acid (1.14 g, 10 mmol) were mixed in 10 ml isopropanol and 
stirred under reflux for 24 h. After cooling to room temperature, the precipitation was 
filtered and recrystallized in CH2Cl2 to afford a light yellow solid 2.5 g (7).
Compound 7 (2.5 g, 7.2 mmol) and Pd/C (0.25 g) were added in a mixture of methanol and 
THF, and stirred under hydrogen atmosphere for 24 h at room temperature. Pd/C was 
filtered by diatomite and the solvents were removed under reduced pressure and the crude 
material was recrystallized in CH2Cl2 to afford compound 8 as a light yellow solid (2.0 g, 
yield for two steps: 64%).
3.2.5 Preparation compound 9—Compound 8 (150 mg, 0.479 mmol) and pyrazine-2-
carboxylic acid (65.3 mg, 0.527 mmol) were dissolved in a mixture of CH2Cl2 and THF. 
HATU (218.5 mg, 0.576 mmol) and DIEA (379 mg, 2.874 mmol) were then added. The 
reaction mixture was stirred at room temperature for 24 h, and was then poured into icy 
water. The precipitation was filtered and washed by dry methanol for several times to afford 
compound 9e as a white solid (101 mg, 51%).
Compounds 9a-9d and 9f-9h were synthetized from different start materials using similar 
procedure as described.
Compound 9a: yield: 43%, mp: 253–255°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.16 (s, 
1H), 9.37 (s, 1H), 9.25 (s, 1H), 8.10 (d, J = 3.3 Hz, 1H), 8.04 (s, 1H), 7.93 (d, J = 6.9 Hz, 
2H), 7.85 (dd, J = 5.7, 8.7 Hz, 2H), 7.49–7.58 (m,3H), 7.41 (d, J = 8.1Hz, 1H), 7.26 (t, J = 
7.5 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 7.08 (t, J = 9.0 Hz, 2H). HR-ESI-MS: m/z = 418.1478 
[M+H]+, calcd for C23H18N5OF2: 418.1474.
Compound 9b: yield: 33%, mp: 242–243°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.50 (s, 
1H), 9.39 (s, 1H), 9.30 (s, 1H), 8.77 (s, 1H), 8.41 (dd, J = 9.0, 12.9 Hz, 2H), 8.09 (d, J = 
10.2 Hz, 2H), 7.84 (t, J = 6.9 Hz, 3H), 7.42 (d, J = 7.2 Hz, 1H), 7.20–7.30 (m, 2H), 7.07 (t, J 
= 8.4 Hz, 3H). HR-ESI-MS: m/z = 463.1329 [M+H]+, calcd for C23H17N6O3F2: 463.1325.
Compound 9c: yield: 99%, mp: > 285°C, 1H NMR (300MHz, DMSO-d6): δ 9.77 (s, 1H), 
9.34 (s, 1H), 9.18 (s, 1H), 8.08 (d, J = 3.6 Hz, 2H), 7.98 (s, 1H), 7.86-7.81 (m, 3H), 7.35 (d, 
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J = 8.1 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.17-7.04 (m, 3H), 6.73 (d, J = 9 Hz, 2H), 2.98 (s, 
6H). HR-ESI-MS: m/z = 461.1885[M+H]+, calcd for C20H21N2O5: 461.1896.
Compound 9d: yield: 48%, mp: 280°C (dec.), 1H NMR (400MHz, DMSO-d6): δ 10.40 (s, 
1H), 9.38 (s, 1H), 9.28 (s, 1H), 8.77 (d, J = 5.2 Hz, 2H), 8.10 (d, J = 3.6 Hz, 1H), 8.04 (s, 
1H), 7.84-7.81 (m, 4H), 7.43 (d, J = 8 Hz, 1H), 7.28-7.19 (m, 2H), 7.10-7.06 (m, 2H). HR-
ESI-MS: m/z = 419.1414[M+H]+, calcd for C20H21N2O5: 419.1426.
Compound 9e: yield: 51%, mp: 265–266°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.47 (s,
1H), 9.39 (s, 1H), 9.28 (d, J = 10.2 Hz, 2H), 8.92 (s, 1H), 8.79 (s, 1H), 8.12 (dd, J = 3.6, 
10.2 Hz, 2H), 7.09 (m, 2H), 7.38 (d, J = 7.5 Hz, 2H), 7.22 (t, J = 8.1 Hz, 1H), 7.07 (t, J = 8.7 
Hz, 2H). HR-ESI-MS: m/z = 420.1381 [M+H]+, calcd for C21H16N7OF2: 420.1379.
Compound 9f: yield: 35%, mp: 272°C (dec.), 1H-NMR (300 MHz, DMSO-d6): δ 9.73 (s, 
1H), 9.36 (s, 1H), 9.17 (s, 1H), 8.08 (d, J = 3.6 Hz, 1H), 7.81–7.87 (m, 3H), 7.32 (d, J = 8.4 
Hz, 1H), 7.07–7.18 (m, 4H), 2.82 (d, J = 11.1 Hz, 2H), 2.17 (s, 3H), 1.88 (t, J = 9.6 Hz, 2H), 
1.60–1.69 (m, 4H). HR-ESI-MS: m/z = 439.2055 [M+H]+, calcd for C23H25N6OF2: 
439.2052.
Compound 9g: yield: 48%, mp: 206–208°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.50 (s, 
1H), 9.36 (s, 1H), 9.19 (s, 1H), 8.08 (d, J = 3.6 Hz, 1H), 7.85-7.82 (m, 3H), 7.36 (d, J = 8.4 
Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 7.20-7.10 (m, 3H), 3.04 (s, 2H), 2.26 (s, 6H). HR-ESI-
MS: m/z = 399.1743 [M+H]+, calcd for C20H21N6OF2: 399.1739.
Compound 9h: yield: 24%, mp: 211–214°C, 1H NMR (300MHz, DMSO-d6): δ 9.57 (s, 
1H), 9.37 (s, 1H), 9.21 (s, 1H), 8.08 (d, J = 3.9 Hz, 1H), 7.85-7.81 (m, 3H), 7.38-7.35 (m, 
1H), 7.16-7.11 (m, 4H), 3.96 (s, 2H), 3.36 (s, 3H). HR-ESI-MS: m/z = 386.1421[M+H]+, 
calcd for C20H21N2O5: 386.1423.
3.2.6 Preparation compound 10—Compound 5d (2.42 g, 10 mmol), m-aminobenzoic 
acid (1.37 g, 10 mmol) and trifluoroacetic acid (1.14 g, 10 mmol) were mixed in 15 mL 
isopropanol and was stirred under reflux for 24 h. After cooling to room temperature, the 
precipitation was filtered and washed by CH2Cl2 for several times to afford compound 10 as 
a white solid (2.5 g, 73%).
3.2.7 Preparation compound 11—Compound 10 (200 mg, 0.585 mmol) and 
morpholine (62 mg, 0.702 mmol) were dissolved in DMF, HATU (267 mg, 0.702 mmol) 
and DIEA (302 mg, 2.34 mmol) were then added. The reaction mixture was stirred at room 
temperature for 24 h and then was poured into icy water. The precipitation was filtered to 
afford compound 11a as a white solid (188 mg, 78%).
Compound 11b-11p were synthetized from different start materials using similar procedure 
as described.
Compound 11a: yield: 78%, mp: 174–176°C, 1H NMR (300MHz, DMSO-d6): δ 9.42 (s, 
1H), 9.37 (s, 1H), 8.12 (d, J = 3.6 Hz, 1H), 7.78-7.74 (m, 3H), 7.65 (d, J = 7.5 Hz, 1H), 7.27 
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(t, J = 7.8 Hz, 1H), 7.15 (t, J = 8.7 Hz, 2H), 6.89 (d, J = 7.8 Hz, 1H), 3.55 (m, 6H), 3.31 (m, 
2H). HR-ESI-MS: m/z = 412.1574[M+H]+, calcd for C20H21N2O5: 412.1580.
Compound 11b: yield: 24%, mp: 184–185°C, 1H NMR (300MHz, DMSO-d6): δ 9.42 (s, 
1H), 9.37 (s, 1H), 8.12 (d, J = 3.6 Hz, 1H), 7.78-7.74 (m, 3H), 7.65 (d, J = 8.1 Hz, 1H), 7.26 
(t, J = 7.8 Hz, 1H), 7.15 (t, J = 8.7 Hz, 2H), 6.86 (d, J = 7.8 Hz, 1H), 3.57 (s, 2H), 3.31 (s, 
2H), 2.26 (s, 4H), 2.16 (s, 3H). HR-ESI-MS: m/z = 425.1883[M+H]+, calcd for 
C20H21N2O5: 425.1896.
Compound 11c: yield: 73%, mp: 197–199°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.41 (s, 
1H), 9.35 (s, 1H), 8.12 (d, J = 3.6 Hz, 1H), 7.74–7.79 (m, 3H), 7.64 (d, J = 8.1 Hz, 1H), 7.25 
(t, J = 8.1 Hz, 1H), 7.15 (t, J = 8.4 Hz, 2H), 6.84 (d, J = 7.5 Hz, 1H), 3.54 (brs, 2H), 3.24 
(brs, 2H), 1.39–1.58 (brs, 6H). HR-ESI-MS: m/z = 410.1794 [M+H]+, calcd for 
C22H22N5OF2: 410.1787.
Compound 11d: yield: 78%, mp: 263–265°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.42 (s, 
1H), 9.38 (s, 1H), 8.12 (d, J = 3.6 Hz, 1H), 7.76 (t, J = 5.1 Hz, 3H), 7.68 (d, J = 8.4 Hz, 1H), 
7.28 (t, J = 8.1 Hz, 1H), 7.16 (t, J = 8.7 Hz, 2H), 6.92 (d, J = 7.2 Hz, 1H), 3.55–3.80 (brs, 
2H), 3.35–3.50 (brs, 2H), 3.00–3.20 (brs, 4H), 2.89(s, 3H). HR-ESI-MS: m/z = 489.1518 [M
+H]+, calcd for C22H23N6O3F2S: 489.1515.
Compound 11e: yield: 39%, mp:161–163°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.42 (s, 
1H), 9.37 (s, 1H), 8.12 (d, J = 3.0 Hz, 1H), 7.74–7.79 (m, 3H), 7.63 (d, J = 7.2 Hz, 1H), 7.26 
(t, J = 7.5 Hz, 1H), 7.13 (t, J = 4.2 Hz, 2H), 6.76–6.83 (m, 1H), 3.50–3.61 (m, 3H), 3.40–
3.45 (m, 3H), 1.97–2.02 (m, 3H), 1.79–1.85 (m, 2H), 1.63 (s, 1H), 1.49 (s, 1H). HR-ESI-
MS: m/z = 467.2015 [M+H]+, calcd for C24H25N6O2F2: 467.2002.
Compound 11f: yield: 34%, mp: 174–176°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.39 (s, 
1H), 9.32 (s, 1H), 8.20 (m, 1H), 8.10 (d, J = 3.6 Hz, 1H), 8.02 (s, 1H), 7.83-7.75 (m, 3H), 
7.34-7.25 (m, 2H), 7.11 (t, J = 8.7 Hz, 2H), 2.36 (t, J = 7.2 Hz, 4H), 2.16 (m, 6H). HR-ESI-
MS: m/z = 413.1899 [M+H]+, calcd for C21H23N6OF2: 413.1896.
Compound 11g: yield: 67%, mp: 212–214°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.39 (s, 
1H), 9.32 (s, 1H), 8.26 (t, J = 5.4 Hz, 1H), 8.11 (d, J = 3.9 Hz, 1H), 8.08 (s, 1H), 7.79–8.83 
(m, 2H), 7.34 (t, J = 7.8 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.11 (t, J = 8.7 Hz, 2H), 4.69 (t, J 
= 5.7 Hz, 1H), 3.48 (dd, J = 6.3, 9.0 Hz, 2H), 3.29 (t, J = 6.0 Hz, 1H). HR-ESI-MS: m/z = 
386.1431 [M+H]+, calcd for C19H18N5O2F2: 386.1423.
Compound 11h: yield: 5.7%, mp:247–248°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.51 (s, 
1H), 9.42 (d, J = 5.7 Hz, 1H), 9.41 (s, 1H), 8.13–8.17 (dd, J = 3.9, 12.0 Hz, 2H), 7.98 (d, J = 
8.4 Hz, 2H), 7.85 (d, J = 6.9 Hz, 1H), 7.79 (dd, J = 4.8, 9.0 Hz, 2H), 7.71 (d, J = 9.3 Hz, 
2H), 7.47 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.07 (t, J = 8.7 Hz, 2H). HR-ESI-MS: 
m/z = 486.1362 [M+H]+, calcd for C24H17N5OF5: 486.1348.
Compound 11i: yield: 50%, mp: 269–271°C, 1H-NMR (300 MHz, DMSO-d6): δ 9.98 (s, 
1H), 9.37 (s, 1H), 8.11 (t, J = 3.6 Hz, 2H), 7.81 (t, J = 8.7 Hz, 3H), 7.61 (d, J = 8.7 Hz, 2H), 
7.44 (d, J = 8.4 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.09 (t, J = 8.7 Hz, 2H), 6.92 (d, J = 8.7 
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Hz, 2H), 3.72 (t, J = 4.8 Hz, 4H), 3.06 (t, J = 4.8 Hz, 4H). HR-ESI-MS: m/z = 503.2010 [M
+H]+, calcd for C27H25N6O2F2: 503.2002.
Compound 11j: yield: 69%, mp: 227–228°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.05 (s, 
1H), 9.39 (d, J = 3.6 Hz, 1H), 8.13 (d, J = 3.6 Hz, 2H), 7.78–7.83 (m, 3H), 7.65 (d, J = 8.4 
Hz, 2H), 7.44 (d, J = 7.5 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.09 (t, J = 8.7 Hz, 2H), 6.90 (d, 
J = 8.7 Hz, 2H). HR-ESI-MS: m/z = 448.1591 [M+H]+, calcd for C24H20N5O2F2: 448.1580.
Compound 11k: yield:47 %, mp:214–216°C, 1H-NMR (300 MHz, DMSO-d6): δ 10.09 (s, 
1H), 9.40 (s, 1H), 8.13 (s, 2H), 7.78–7.81 (m, 3H), 7.42 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.5 
Hz, 1H), 7.07–7.13 (m, 4H), 6.25 (s, 1H), 3.72 (s, 6H). HR-ESI-MS: m/z = 478.1697 [M
+H]+, calcd for C25H22N5O3F2: 478.1685.
Compound 11l: yield: 45%, mp: 224–226°C, 1H-NMR ( 300 MHz, DMSO-d6): δ 10.07 (s, 
1H), 9.39 (s, 2H), 8.12 (t, J = 3.9 Hz, 2H), 7.78–7.82 (m, 3H), 7.41 (t, J = 1.8 Hz, 2H), 7.35 
(t, J = 7.8 Hz, 1H), 7.16 (dd, J = 2.1, 8.4 Hz, 1H), 7.09 (t, J = 9.0 Hz, 2H), 6.87 (d, J = 8.4 
Hz, 1H), 5.99 (s, 2H). HR-ESI-MS: m/z = 462.1383 [M+H]+, calcd for C24H18N5O3F2: 
462.1372.
Compound 11m: yield: 25%, mp: 224–226°C, 1H-NMR (300 MHz, CD3OD): δ 8.13 (s, 
1H), 7.87 (d, J = 3.0 Hz, 1H), 7.65 (d, J = 1.5 Hz, 2H), 7.56–7.60 (m, 3H), 7.38 (d, J = 7.2 
Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.10 (s, 1H), 6.88 (t, J = 8.7 Hz, 2H). HR-ESI-MS: m/z = 
486.0710 [M+H]+, calcd for C23H16N5OF2Cl2: 486.0695.
Compound 11n: yield: 26%, mp: 131–133°C, 1H-NMR ( 300 MHz, DMSO-d6): δ 10.58 (s, 
1H), 9.39 (d, J = 5.7 Hz, 2H), 8.36 (d, J = 3.6 Hz, 1H), 8.12–8.19 (m, 3H), 7.77–7.86 (m, 
4H), 7.74 (d, J = 7.8 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 7.05–7.16 (m, 3H). HR-ESI-MS: m/z 
= 419.1426 [M+H]+, calcd for C22H17N6OF2: 419.1426.
Compound 11o: yield: 100%, mp: > 285°C, 1H NMR(300MHz, DMSO-d6): δ 9.32 (s, 1H), 
9.18 (s, 1H), 8.23 (s, 1H), 8.09 (d, J = 3.6 Hz, 1H), 7.88-7.84 (m, 2H), 7.67 (d, J = 7.5 Hz, 
2H), 7.20-7.18 (m, 2H), 7.15-7.07 (m, 3H), 6.60 (s, 1H). HR-ESI-MS: m/z = 425.0984[M
+H]+, calcd for C20H21N2O5: 425.0991.
Compound 11p:yield: 48%, mp: 221–223°C, 1H-NMR ( 300 MHz, DMSO-d6): δ 10.06 (s, 
1H), 9.36 (s, 1H), 9.23 (s, 1H), 8.10 (d, J = 3.6 Hz, 1H), 8.03 (s, 1H), 7.82 (dd, J = 4.8, 9.0 
Hz, 2H), 7.07–7.43 (m, 7H), 3.96 (s, 3H). HR-ESI-MS: m/z = 422.1538 [M+H]+, calcd for 
C21H18N7OF2: 422.1535.
3.3 Biological evaluation
3.3.1 Cytotoxic activity assay—The following human tumor cell lines were used in the 
assay: A549 (lung cancer), DU-145 (prostate cancer), KB (nasopharyngeal carcinoma) and 
KBvin (vincristine-resistant KB subline). All cell lines were obtained from the Lineberger 
Comprehensive Cancer Center (UNC-CH) or from ATCC (Rockville, MD) and were 
cultured in RPMI-1640 medium supplemented with 25 mM HEPES, 0.25% sodium 
bicarbonate, 10% fetal bovine serum, and 100 mg/mL kanamycin.
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The cytotoxicity assay was performed by following experimental protocols described in the 
reference24. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at 
densities of 1500–7500 cells per well with compounds added from DMSO-diluted stock. 
After 3 days in culture, attached cells were fixed with cold 50% trichloroacetic acid and then 
stained with 0.4% sulforhodamine B (SRB). The absorbance at 562 nm was measured using 
a microplate reader after solubilizing the bound dye. The mean IC50 is the concentration of 
agents that reduces cell growth by 50% under the experimental conditions and it is the 
average from three independent determinations that are reproducible and statistically 
significant.
3.3.2 CDK2/Cyclin E1 kinase assay—The kinase assay against CDK2/cyclinE1 was 
performed by following experimental protocols described in the reference25. The 
compounds were mixed with the enzyme (2.28 ng) in a buffer containing 40 mM Hepes/
Tris(pH 7.4), 0.8 mM EGTA/Tris, 8 mM MgCl2, 1.6 mM DTT and 0.008% Tween 20. 
Thereafter, the reaction was initiated by adding 100 nM of the substrate Ulight-
CFFKNIVTPRTPPPSQGK-amide (MBP) and 10 μM ATP, and the mixture was incubated 
for 15 minutes at room temperature. For control basal measurements, the enzyme was 
omitted from the reaction mixture. Following incubation, the reaction was stopped by 
adding 13 mM EDTA. After 5 minutes, the anti-phospho-MBP antibody labeled with 
europium chelate was added. After 60 more minutes, the fluorescence transfer was measured 
at λex=337 nm, λem=620 nm and λem=665 nm using a microplate reader (Envision, Perkin 
Elmer). The enzyme activity was determined by dividing the signal measured at 665 nm by 
that measured at 620 nm (ratio). The results were expressed as a percent inhibition of the 
control enzyme activity. The compounds were tested in each experiment at several 
concentrations to obtain an inhibition curve from which the IC50 values were calculated.
3.3.3 CDK9/Cyclin T1 kinase assay—The kinase assay against CDK9/cyclinT1 was 
performed by following experimental protocols described in the reference26. The 
compounds were mixed with the enzyme (21.72 ng) in a buffer containing 40 mM Hepes/
Tris(pH 7.4), 0.8 mM EGTA/Tris, 8 mM MgCl2, 1.6 mM DTT and 0.008% Tween 20. 
Thereafter, the reaction was initiated by adding 100 nM of the substrate Ulight-
CFFKNIVTPRTPPPSQGK-amide (MBP) and 10 μM ATP, and the mixture was incubated 
for 90 minutes at room temperature. For control basal measurements, the enzyme was 
omitted from the reaction mixture. Following incubation, the reaction was stopped by 
adding 13 mM EDTA. After 5 minutes, the anti-phospho-MBP antibody labeled with 
europium chelate was added. After 60 more minutes, the fluorescence transfer was measured 
at λex=337 nm, λem=620 nm and λem=665 nm using a microplate reader (Envision, Perkin 
Elmer). The enzyme activity was determined by dividing the signal measured at 665 nm by 
that measured at 620 nm (ratio). The results were expressed as a percent inhibition of the 
control enzyme activity. The compounds were tested in each experiment at several 
concentrations to obtain an inhibition curve from which the IC50 values were calculated.
3.3.4 Anti-HIV-1 assay—The anti-HIV-1 assay was performed with NL4-3 virus by 
following experimental protocols described in the reference27. A 96-well microtiter plate 
was used to set up the HIV-1 NL4-3 replication assay. HIV-1 NL4-3 at a multiplicity of 
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infection (MOI) of 0.01 was used to infect MT4 cells. Culture supernatants were collected 
on day 4 post infection for the p24 assay using an ELISA kit from ZeptoMetrix Corporation 
(Buffalo, New York).
3.4 Molecular modeling
The structures of compounds 6d and 9g were generated and molecular docking was 
performed with the Discovery Studio 2.5 software package (Accelrys, San Diego, USA). 
The structures of CDK2 and CDK9 were obtained from the Protein Data Bank (PDB codes: 
4BCP and 4BCG). The docking calculation was carried out with the CDOCK protocol. 
Default settings were used. All calculations were performed on a DELL Precision T5500 
workstation.
4. Conclusions
Thirty novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamine derivatives were designed as 
potential CDK, especially CDK9 inhibitors. Cytotoxicity for all the target compounds was 
measured with the SRB assay. Compounds with GI50 values against tumor cells at lower 
micromolar to submicromolar level were identified. Some most cytotoxic compounds 
exhibited potent inhibitory activities against both CDK2/cyclin E1 and CDK9/cyclin T1. 
Good correlation between cellular and molecular activities was observed. Noticeable 
inhibition against HIV-1 replication was also detected in an anti-HIV-1 assay, and there 
appeared to be a correlation between selective CDK9 inhibition and the anti-HIV-1 
therapeutic index. Docking studies on this compound class hinted the existence of 
alternative binding poses and explained the realization of isotype selectivity, which provided 
new clues for further structural optimization.
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Pharmacophore models for CDK9 inhibitors. (a) a 3D-QSAR pharmacophore (with 
hydrogen-bond acceptors represented in green and hydrophobic aromatic features 
represented in cyan) derived from diverse CDK9 inhibitors and its mapping with FVP; (b) 
Key interactions between FVP and CDK9 revealed by their co-crystal structure; (c) a 
composite pharmacophore extracted from the interaction mode shown in (b). The hydrogen 
bond forming atoms are represented in green, the hydrophobic aromatic center is represented 
in cyan and the positively charged center is represented in purple.
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Figure 2. General formula of target compounds and their pharmacophoric features
R1 contains a hydrogen bond forming atom and/or a positively charged center. Various R2 
and R3 substituents are incorporated on the two phenyl rings to meet the pharmacophoric 
requirements.
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Alternative interaction modes of 9g as suggested by the docking study.
Gao et al. Page 17














Interaction modes of 6d with CDK2 (a) and CDK9 (b) as suggested by the docking study.
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Reagents and conditions: a. morpholine or N-methyl piperazine, CuI, L-proline, K2CO3, 
DMSO, N2, 100–110°C; b. Pd/C, H2, CH3OH or THF; c. the appropriate amine, Et3N, 
EtOH; d. CF3COOH, i-PrOH or 2-BuOH, reflux; e. 3-Nitroaniline (for 7) or 3-aminobenzoic 
acid (for 10), CF3COOH, i-PrOH or 2-BuOH, reflux; f. the appropriate acid or amine, 
DIEA, HATU, DMF.
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Table 4













FVP 0.13 4.59 (nM)
*
The IC50 value was interpolated from dose-response data with at least six different concentrations. Each test was performed in duplicate. Data 
represent the average of duplicate measurements.
#
No significant inhibition was observed at the concentration of 10 μM.
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Table 5
Anti-HIV-1 activities of selected compounds.
Compd. EC50* IC50* SelectivityCDK2/CDK9
TI#
(μM)
6d 1.37 ± 0.42 10.22 ± 1.27 17.7 7.45
11e 7.08 ± 1.54 15.45 ± 1.72 3.9 2.18
11f 3.15 ± 0.66 3.40 ± 0.27 2.7 1.08
FVP 0.015 ± 0.005 0.067 ± 0.007 28.3 4.47
*
The EC50 and IC50 values are the average of three independent measurements;
#
TI, therapeutic index, the ratio of the IC50 value to the EC50 value.
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